The use of PSA testing over more than 20 years: A population-based study in North-Eastern Italy.
Prostate-specific antigen
prostate biopsy
prostate cancer
screening
time trend
Journal
Tumori
ISSN: 2038-2529
Titre abrégé: Tumori
Pays: United States
ID NLM: 0111356
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
medline:
21
7
2023
pubmed:
12
10
2022
entrez:
11
10
2022
Statut:
ppublish
Résumé
To describe the practice of prostate-specific antigen (PSA) testing over more than 20 years in Friuli Venezia Giulia (FVG), North-Eastern Italy. A population-based, ecological study was conducted using information derived from regional administrative health-related databases. Data on PSA and prostate biopsies performed on resident men aged ⩾45 years from 1998 to 2019 were retrieved. PSA and biopsy rates were calculated as the number of men who had at least one such procedure in each calendar year over the mean resident male population of the same year. Temporal trends were analyzed using joinpoint regression (annual percentage change -APC). A total of 2,502,670 PSA were made between 1998 to 2019 in men aged ⩾45 years. The number of PSA steadily increased from 51,055 in 1998-1999 to 134,504 in 2010-2011, then dropped to 122,080 in 2018-2019. Significant changes in the slopes of PSA rates emerged in 2002 and 2009: the largest increase occurred during 1998-2002 (APC 18.4), followed by a smaller increase in 2002-2009 (APC 3.4) and a subsequent reduction (APC -2.5). Similar patterns emerged for all ages, but the decrease since 2009 was smaller for men aged ⩾65 years. An upward trend emerged in biopsy rate from 1998 to 2001 (APC 13.0), followed by a smaller increase until 2007 (APC 5.7) and a subsequent decrease. Biopsies as percentage of PSA decreased from 3.2% to 2.2%, particularly in those aged ⩾75 years. Although overall declining PSA rates have been observed in FVG since 2009, rates remained higher in the ⩾65-year-old group than in the 45-64-year-old group.
Identifiants
pubmed: 36217669
doi: 10.1177/03008916221128343
pmc: PMC10363938
doi:
Substances chimiques
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
406-412Références
CA Cancer J Clin. 2010 Mar-Apr;60(2):70-98
pubmed: 20200110
N Engl J Med. 2009 Mar 26;360(13):1310-9
pubmed: 19297565
Epidemiol Prev. 2009 Jul-Oct;33(4-5 Suppl 1):1-168
pubmed: 20124636
Eur Urol. 2014 Jun;65(6):1046-55
pubmed: 24439788
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Natl Cancer Inst. 2011 Mar 16;103(6):520-3
pubmed: 21357307
Int J Cancer. 2016 Mar 15;138(6):1388-400
pubmed: 26488767
Tumori. 2019 Apr;105(2):121-137
pubmed: 30917768
J Med Ethics. 2020 Jul 6;:
pubmed: 32631969
Eur Urol. 2013 Sep;64(3):347-54
pubmed: 23856038
Cancer. 2018 Jul 1;124(13):2733-2739
pubmed: 29781117
Ann Intern Med. 2008 Aug 5;149(3):185-91
pubmed: 18678845
JAMA. 2015 Nov 17;314(19):2054-61
pubmed: 26575061
J Clin Oncol. 2015 Aug 1;33(22):2416-23
pubmed: 26056181
Tumori. 2008 Jul-Aug;94(4):518-22
pubmed: 18822688
BJU Int. 2007 Dec;100(6):1254-8
pubmed: 17979925
Am J Prev Med. 2015 Oct;49(4):520-5
pubmed: 25960395
JAMA Surg. 2017 Feb 1;152(2):192-198
pubmed: 27806151
BJU Int. 2017 Jan;119(1):110-115
pubmed: 27454454
Cancer Epidemiol. 2016 Feb;40:166-72
pubmed: 26771313
Eur J Cancer Prev. 2004 Oct;13(5):383-6
pubmed: 15452450
Eur J Cancer Prev. 2010 Nov;19(6):413-6
pubmed: 20679895
Eur Urol. 2012 Nov;62(5):745-52
pubmed: 22704366
J Urol. 2013 Aug;190(2):419-26
pubmed: 23659877
BMJ. 2009 Sep 24;339:b3601
pubmed: 19778971
JAMA. 2018 May 8;319(18):1901-1913
pubmed: 29801017
JAMA. 2018 May 8;319(18):1914-1931
pubmed: 29801018
J Med Screen. 2010;17(1):50-1
pubmed: 20356946
Eur Urol. 2019 Jul;76(1):43-51
pubmed: 30824296